Neuroendocrine Tumors (NET)

Neuroendocrine tumors vary from indolent to aggressive NEC — grade and differentiation rewrite the playbook.

NETs secrete or silently grow along the gut and pancreas with a wide biological spectrum. Grade (Ki-67/mitoses) and differentiation separate relatively indolent NETs from high-grade neuroendocrine carcinomas that need different chemotherapy mindsets. Functional syndromes (carcinoid, insulinoma, etc.) add hormone-control tasks to tumor control tasks. These tumors follow sarcoma or neuroendocrine rules, not generic adenocarcinoma recipes. Write down your top three questions before the appointment.

NET — educational figure — NET · educational illustration

Who may be a candidate?

People evaluating neuroendocrine tumors (net) within GIST and NET
International patients preparing a structured second-opinion visit
Patients comparing observation, medical care, and procedural options

Possible advantages

Explains how neuroendocrine tumors (net) fits into the GIST and NET care pathway
Supports informed consent with alternatives and recovery themes
Highlights red flags that should trigger urgent contact

Limits & realistic expectations

Cannot replace examination, imaging, or pathology
Local protocols and tumor-board decisions may refine timing
Outcomes vary with anatomy, stage, and comorbidity

Step-by-step overview

1
Define the clinical question
Confirm why neuroendocrine tumors (net) is being discussed now — diagnosis, staging, treatment, or surveillance.
2
Gather records
Collect imaging, endoscopy, pathology, and prior operative notes before decisions lock.
3
Risk-stratify
Match urgency to red flags, labs, and imaging rather than labels alone.
4
Choose a pathway
Compare observation, medical therapy, endoscopy, and surgery with expected recovery.
5
Plan follow-up
Agree on review timing, warning symptoms, and who to call after hours.

Key points

How neuroendocrine tumors (net) fits the pathway
Tap for details
In GIST and NET, “Neuroendocrine Tumors (NET)” is a decision node inside a longer journey: symptoms, confirmation, risk stratification, treatment choice, and follow-up. Reading this chapter alongside the hub overview helps you ask better questions in clinic.
What clinicians weigh
Tap for details
GIST and NET follow sarcoma or neuroendocrine rules, not ordinary adenocarcinoma recipes; pathology and genotype or grade unlock therapy. Your age, comorbidities, prior operations, imaging quality, pathology details, and personal goals can reasonably change the sequence even when the label is the same.
- Disease extent and urgency
- Fitness for anesthesia or procedure
- Alternatives and expected recovery
- Follow-up intensity you can complete
Warning signs worth urgent review
Tap for details · key note inside
Severe progressive pain, fever with rigidity, vomiting with obstipation, heavy bleeding, sudden breathlessness, or a rapidly worsening wound/stoma problem should not wait for a routine slot. When in doubt, seek urgent assessment and bring prior reports.
- Severe progressive pain
- Fever with peritoneal signs
- Vomiting with inability to pass stool/gas
- Heavy bleeding or collapse
Practical preparation for your visit
Tap for details
Bring endoscopy or operative reports, pathology, imaging discs, medication lists, and a short written list of priorities. Ask how this step changes if molecular results, MRI, or second-look findings differ from the preliminary plan.
Shared decisions and realistic expectations
Tap for details
Educational pages cannot replace examination. Two patients with the same neuroendocrine tumors (net) label may leave with different plans after staging. Ask what success looks like at three months and one year, and what the rescue plan is if the first pathway fails.
Important
Tap for details · key note inside
Educational information only — not a substitute for clinical evaluation or personalized advice.

Frequently asked questions

What is the difference between NET and NEC?
Tap for details
Grade and differentiation separate relatively indolent NETs from aggressive neuroendocrine carcinomas with different treatments.
Do all NETs produce hormones?
Tap for details
No. Functional and non-functional tumors are managed differently.
Why is Ki-67 important?
Tap for details
It helps grade the tumor and shapes therapy intensity.
Is surgery always first?
Tap for details
Not for every stage; systemic and liver-directed options appear in selected algorithms.

More chapters in this hub

Appointment / info

+90 542 725 50 70 WhatsApp Tumor board Back to hub →Full Turkish chapter →

Educational information only; not a substitute for clinical evaluation.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.